Surveyed Infectious Disease Specialists Anticipate Changes in Their Future Prescribing Patterns For Treating MRSA Infections
MALVERN, Pa., June 22 /PRNewswire/ — Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that surveyed infectious disease specialists anticipate changes in their future prescribing patterns for treating hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections. Physicians want to continue gaining experience with currently branded anti-infectives such as Cubist’s Cubicin, Theravance/Astellas’s Vibativ, and Pfizer’s Zyvox and Tygacil. These drugs offer potent MRSA activity but are often placed on restricted formulary limiting their use to confirmed cases and treatment failures.
“Surveyed infectious disease specialists believe that increases in the incidence of MRSA infections and failures with vancomycin (the current standard of care) could be more common in the future, potentially driving physicians to shift prescribing away from vancomycin and toward these branded agents (Cubicin, Vibativ, Zyvox and Tygacil),” said Lisa Arias, analyst.
The new report entitled Hospital Anti-Infectives Insight Series: MRSA Infections also finds that the most important factors that influence physicians’ treatment selection are activity against MRSA, safety and tolerability, bactericidal activity, and a high barrier to resistance. Emerging drugs that can strongly demonstrate these attributes or improve upon them compared with current therapies could be well-received in the MRSA market. In contrast, factors that offer convenience, such as oral formulation and dosing schedule, are not as important to infectious disease specialists when selecting therapy and therefore are not as influential when treating MRSA infections.
About the Report
AMR’s Hospital Anti-Infectives Insight Series: MRSA Infections analyzes hospital antibiotic prescribing patterns using AMR’s comprehensive and highly detailed clinical data in conjunction with primary research and extensive understanding of emerging therapies and forecasts. This report contains U.S. data and examines the reasons behind physicians’ product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.
AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources, Inc. consists of two business units. The Medical Technology business unit includes Millennium Research Group, the global authority on medical device market intelligence. The Biopharma business unit consists of five companies: Arlington Medical Resources, a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries; Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues; Fingertip Formulary, the leading provider of access to and insight into formulary data in the United States; HealthLeaders-InterStudy, the leading provider of managed care market intelligence; and Manhattan Research, the leading provider of access to physician and consumer opinions on the global healthcare market. For more information, please visit www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Christopher Comfort 781-296-2597 email@example.com
SOURCE Decision Resources, Inc.